Dual pancreatic adrenergic and dopaminergic signaling as a therapeutic target of bromocriptine

Bromocriptine is approved as a diabetes therapy, yet its therapeutic mechanisms remain unclear. Though bromocriptine’s actions have been mainly attributed to the stimulation of brain dopamine D(2) receptors (D2R), bromocriptine also targets the pancreas. Here, we employ bromocriptine as a tool to el...

Descripción completa

Detalles Bibliográficos
Autores principales: Aslanoglou, Despoina, Bertera, Suzanne, Friggeri, Laura, Sánchez-Soto, Marta, Lee, Jeongkyung, Xue, Xiangning, Logan, Ryan W., Lane, J. Robert, Yechoor, Vijay K., McCormick, Peter J., Meiler, Jens, Free, R. Benjamin, Sibley, David R., Bottino, Rita, Freyberg, Zachary
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9379584/
https://www.ncbi.nlm.nih.gov/pubmed/35982797
http://dx.doi.org/10.1016/j.isci.2022.104771

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9379584/
https://www.ncbi.nlm.nih.gov/pubmed/35982797
http://dx.doi.org/10.1016/j.isci.2022.104771

Ejemplares similares